Investor Relations
The Investor Relations department of Evotec SE acts as an interface between the company and the capital markets. Our extensive investor relations work focuses on an active, regular, comprehensive and transparent dialogue with our stakeholders, including shareholders, existing and potential investors, analysts, banks and the financial press. The various interest groups are provided with all important information about the company and have the opportunity to form a comprehensive picture of the company as well as to assess its future development in the best possible way.
Our Equity Story
- Evotec is advancing drug discovery and development with a unique B2B model with focus on pipeline-building, offering specific solutions in the R&D continuum, as well as providing CRO/CDMO services.
- We have built a “shared economy” in R&D with more than 500 partners working on our platform at the same time.
- Our long-term aspiration is to develop disease-modifying therapies and potential cures; for as long as even a single disease remains untreated, the claim #researchneverstops will hold.
- Our mission is to discover and develop medicines that matter in efficient collaborations together with its partners, where it focuses on data-driven disease understanding, precision medicine and early disease relevance to bring probabilities of success up (“PoS up”).
- The combination of our capabilities and unique business model is just at the beginning to deliver strong operational growth and value creation for all our stakeholders.
Our Growth Strategy
Evotec’s growth strategy aims to cover the entirety of the early R&D value chain to impact patients’ lives by addressing a broad range of disease areas in collaboration with its partners and by utilizing a modality-agnostic approach. In addition, by leveraging the value of its platforms and sharing intellectual property, Evotec seeks to de-risk its portfolio through the breadth and diversity of pipeline assets. The Company aims to have over 170 pipeline assets by the end of 2025, with its first royalties to be received in 2025.
Evotec’s team aspires to impact patient’s lives in four main areas in particular:
- PanOmics-driven drug discovery for deep disease understanding and effective therapies
- iPSC "off-the-shelf" cell therapy based on induced-pluripotent stem cells
- Just – Evotec Biologics artificial intelligence and continuous manufacturing for better access to biologics
- End-to-End Shared R&D integrated business-to-business platform for increased probability of success from target to the clinic
Evotec's strategic goals include:
- Establishing Evotec as a best-in-class, integrated precision medicine platform
- Strengthening our position as most efficient partner to the life sciences sector
- Expanding the breadth of co-owned assets
- Further innovation in biologics by Just - Evotec Biologics
- Identifying risk-balanced, high-reward opportunities through equity investments
- Leveraging the synergies between Evotec’s businesses
